Seeking Alpha

Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss...

Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss excluding compensation and derivative-value issues), roughly in line with analyst expectations of a $0.22-$0.25 loss. The late-stage biopharma noted an FDA approval for a use of its Vascepa capsules in treating hypertriglyceridemia, and the development of eight new patents to go alone with 30 other applications pending.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs